Advertisement

Uterine Sarcomas: Experience from a Tertiary Cancer Care Center from India

  • Syed NusrathEmail author
  • Sandeep Bafna
  • R. Rajagopalan
  • Subramanyeshwar Rao Thammineedi
  • K. V. V. N. Raju
  • Sujit Chyau Patnaik
  • Satish Pawar
  • Yugandhar Reddy
  • Ramachandra Nagaraju Chavali
  • Sudha S. Murthy
Original Article
  • 1 Downloads

Abstract

Uterine sarcomas are uncommon and aggressive tumors comprising 3–7% of all uterine malignancies. The aim is to evaluate clinical presentation, histopathologic pattern, recurrence pattern, and outcome of patients with uterine sarcomas presenting to a tertiary care cancer center over an 8-year period. A total of 11 cases of uterine sarcoma were diagnosed. The median age of patients at presentation was 51 years (range 30–67 years). Six patients had leiomyosarcoma (54.5%), 4 had endometrial stromal sarcoma (36%), and 1 had adenosarcoma (9%). The main presenting symptoms were abnormal vaginal bleeding, low abdominal pain, and white discharge. Median follow-up was 11 months ranging from 3 to 200 months. Median survivals for leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma were 6.5, 18, and 56 months. The 3- and 5-year survival by Kaplan–Meier survival analysis of the entire cohort was 30 and 20%. The mitotic index, age, adjuvant therapy (chemotherapy, radiotherapy), and performance of pelvic nodal dissection did not impact survival significantly in the patient with leiomyosarcoma. Stage and histology had the strongest bearing on survival and leiomyosarcoma has the worst survival, whereas adenosarcoma had the best prognosis. Adequately powered prospective studies are required to define the role of radiation therapy and chemotherapy in this rare disease.

Keywords

Uterine sarcoma Carcinosarcoma Endometrial stromal sarcoma Leiomyosarcoma Adenosarcoma 

Abbreviations

CS

Carcinosarcoma

ESS

Endometrial stromal sarcoma

LMS

Leiomyosarcoma

AS

Adenosarcoma

DFS

Disease-free survival

OS

Overall survival

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Harlow BL, Weiss NS, Lofton S (1986) The epidemiology of sarcomas of the uterus. J Natl Cancer Inst 76:399–402PubMedGoogle Scholar
  2. 2.
    Abeler VM, Røyne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB (2009) Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 54:355–364CrossRefGoogle Scholar
  3. 3.
    Brooks SE, Zhan M, Cote T, Baquet CR (2004) Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol 93:204–208CrossRefGoogle Scholar
  4. 4.
    D'Angelo E, Prat J (2010) Uterine sarcomas: a review. Gynecol Oncol 116(1):131–139CrossRefGoogle Scholar
  5. 5.
    Cantrell LA, Blank SV, Duska LR (2015) Uterine carcinosarcoma: a review of the literature. Gynecol Oncol 137(3):581–588CrossRefGoogle Scholar
  6. 6.
    Prat J (2009) FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 104(3):177–178CrossRefGoogle Scholar
  7. 7.
    Biswas A, Patel F, Kumar P, Srinivasan R, Bera A, Sharma SC, Rajwanshi A (2013) Uterine sarcoma-current management and experience from a regional cancer centre in North India. Arch Gynecol Obstet 288(4):873–882CrossRefGoogle Scholar
  8. 8.
    Sharma DN, Rath GK, Kumar S, Kumar L, Bhatla N, Gandhi AK, Hariprasad R (2011) Clinical outcome of patients with uterine sarcomas. J Cancer Res Ther 7(3):270–274CrossRefGoogle Scholar
  9. 9.
    Leitao MM, Sonoda Y, Brennan MF, Barakat RR, Chi DS (2003) Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecol Oncol 91:209–212CrossRefGoogle Scholar
  10. 10.
    Goff BA, Rice LW, Flelschhacker D, Muntz HG, Falkenberry SS, Nikrui N, Fuller AF Jr (1993) Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol Oncol 50(1):105–109CrossRefGoogle Scholar
  11. 11.
    Shah JP, Bryant CS, Kumar S, Ali-Fehmi R, Malone JM Jr, Morris RT (2008) Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma. Obstet Gynecol 112(5):1102–1108CrossRefGoogle Scholar
  12. 12.
    Barney B, Tward JD, Skidmore T, Gaffney DK (2009) Does radiotherapy or lymphadenectomy improve survival in endometrial stromal sarcoma? Int J Gynecol Cancer 19(7):1232–1238CrossRefGoogle Scholar
  13. 13.
    Leath CA, Huh WK et al (2007) A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol 105(3):630–634CrossRefGoogle Scholar
  14. 14.
    Agarwal R, Rajanbabu et al (2017) Endometrial stromal sarcoma-a retrospective analysis of factors affecting recurrence. Eur J Obstet Gynecol Reprod Biol 216:92–97CrossRefGoogle Scholar
  15. 15.
    Reed NS, Mangioni C, Malmstrom H et al (2008) Phase III randomized study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: a European Organization for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 44:808–818CrossRefGoogle Scholar
  16. 16.
    Pautier P, Floquet A, Gladieff L, Bompas E, Ray-Coquard I, Piperno-Neumann S, Selle F, Guillemet C, Weber B, Largillier R, Bertucci F, Opinel P, Duffaud F, Reynaud-Bougnoux A, Delcambre C, Isambert N, Kerbrat P, Netter-Pinon G, Pinto N, Duvillard P, Haie-Meder C, Lhomme C, Rey A (2013) A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. Ann Oncol 24:1099–1104CrossRefGoogle Scholar
  17. 17.
    Littell RD, Tucker LY, Raine-Bennett T, Palen TE, Zaritsky E, Neugebauer R, Embry-Schubert J, Lentz SE (2017) Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: trends and survival outcomes. Gynecol Oncol 147(1):11–17CrossRefGoogle Scholar
  18. 18.
    Bogani G, Fucà G, Maltese G, Ditto A, Martinelli F, Signorelli M, Chiappa V, Scaffa C, sabatucci I, Lecce F, Raspagliesi F, Lorusso D (2016) Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: a systematic review and meta-analysis. Gynecol Oncol 143(2):443–447CrossRefGoogle Scholar
  19. 19.
    Seagle BLL, Sobecki-Rausch J, Strohl AE, Shilpi A, Grace A, Shahabi S (2017) Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study. Gynecol Oncol 145(1):61–70CrossRefGoogle Scholar
  20. 20.
    Hensley ML, Wathen JK, Maki RG, Araujo DM, Sutton G, Priebat DA, George S, Soslow RA, Baker LH (2013) Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer 119(8):1555–1561CrossRefGoogle Scholar
  21. 21.
    Friedman CF, Hensley ML (2018) Options for adjuvant therapy for uterine leiomyosarcoma. Curr Treat Options in Oncol 19(2):7CrossRefGoogle Scholar
  22. 22.
    Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litière S, Hermans C, Fisher C, Hogendoorn PC, dei Tos A, van der Graaf W, European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (2014) European organisation and treatment of cancer soft tissue and bone sarcoma group. Lancet Oncol 15(4):415–423CrossRefGoogle Scholar
  23. 23.
    Hensley ML, Ishill N et al (2009) Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol 112(3):563–567CrossRefGoogle Scholar
  24. 24.
    Chu MC, Mor G, Lim C, Zheng W, Parkash V, Schwartz PE (2003) Low-grade endometrial stromal sarcomas: hormonal aspects. Gynecol Oncol 90(1):170–176CrossRefGoogle Scholar
  25. 25.
    Yamaguchi M, Erdenebaatar C, Saito F, Motohara T, Miyahara Y, Tashiro H, Katabuchi H (2015) Long-term outcome of aromatase inhibitor therapy with letrozole in patients with advanced low-grade endometrial stromal sarcoma. Int J Gynecol Cancer 25(9):1645–1651CrossRefGoogle Scholar
  26. 26.
    Pink D, Lindner T et al (2006) Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol 101(3):464–469CrossRefGoogle Scholar

Copyright information

© Indian Association of Surgical Oncology 2019

Authors and Affiliations

  • Syed Nusrath
    • 1
    Email author
  • Sandeep Bafna
    • 1
    • 2
  • R. Rajagopalan
    • 1
  • Subramanyeshwar Rao Thammineedi
    • 1
  • K. V. V. N. Raju
    • 1
  • Sujit Chyau Patnaik
    • 1
  • Satish Pawar
    • 1
    • 3
  • Yugandhar Reddy
    • 1
    • 3
  • Ramachandra Nagaraju Chavali
    • 1
  • Sudha S. Murthy
    • 4
  1. 1.Department of Surgical OncologyBasavatarakam Indo American Cancer Hospital and Research InstituteHyderabadIndia
  2. 2.Apollo hospitalChennaiIndia
  3. 3.American Oncology InstituteHyderabadIndia
  4. 4.Department of Laboratory MedicineBasavatarakam Indo American Cancer Hospital and Research InstituteHyderabadIndia

Personalised recommendations